AMA Webinar Provides Update on COVID-19 Therapeutics and Other Treatment Options

Translate to Spanish or other 102 languages!

Fact-based insights on COVID-19 therapeutic drugs and other treatment options from the nation’s highest-ranking subject matter experts. Image for illustration purposes.
Paxlovid and Molnupiravir—two therapeutics used in treating COVID-19. Image for illustration purposes.

Mega Doctor News

- Advertisement -

The AMA’s COVID-19 webinar series continues this week by bringing the physician community the latest fact-based insights on COVID-19 therapeutic drugs and other treatment options from the nation’s highest-ranking subject matter experts.

During the tenth episode in the webinar series, AMA Immediate Past President Susan R. Bailey, M.D. will host several infectious disease experts from the Food and Drug Administration (FDA) to provide physicians with the most up-to-date information on Paxlovid and Molnupiravir—two therapeutics used in treating COVID-19. They will also discuss alternative treatment options for high-risk outpatients with mild-moderate COVID-19. 

 
What: AMA webinar series, episode 10: therapeutics and other treatment options

When:  Tuesday, February 1, 2022, 1 p.m. Central | 2 p.m. Eastern

Who:   Susan R. Bailey, M.D., AMA Immediate Past President

- Advertisement -

Stephanie Troy, M.D., FDA Senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs

Aimee Hodowanec, M.D., FDA Senior medical officer, Division of Antivirals, Office of Infectious Disease in the Center for Drug Evaluation and Research’s Office of New Drugs

John Farley, M.D., M.P.H., FDA Director of Infectious Diseases in the Center for Drug Evaluation and Research’s Office of New Drugs

Registration: To watch the live webinar, register here

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Mayo Clinic Study Sheds New Light on Memory Loss

A new framework, published in Brain, could reshape researchers' understanding of how the brain creates memories and experiences, and how disruptions in this process may indicate Alzheimer’s disease and other forms of dementia.

United States and Mexico Lose Measles Elimination Status Amid Continued Outbreaks

The United States, Mexico and Bolivia have lost their measles elimination status after the highly contagious virus circulated continuously for more than 12 months, the Pan American Health Organization (PAHO) announced November 17, 2026.

Eating and sleeping later associated with increased health risks

Staying up late and eating later in the evening could increase the risk of metabolic syndrome, a term that refers to conditions that increase the risk of type 2 diabetes, cardiovascular disease, and high cholesterol.

Health Officials Release Joint Statement Regarding Loss of U.S. Measles Elimination Status

CDC and its partners are committed to stopping measles outbreaks, protecting Americans, and regaining measles elimination status.
- Advertisement -